Benazepril hydrochloride Le Vet 20 mg tablets for dogs

Authorised

- Benazepril hydrochloride

Product identification

Medicine name:
Benazepril hydrochloride Le Vet 20 mg tablets for dogs
Benakor vet. 20 mg tabletter til hund

Active substance:
Benazepril hydrochloride

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Benazepril hydrochloride
20.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QC09AA07

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Norway

Package description:

Carton box containing 5 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 6 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 5 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 2 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 1 PVC-PE-PVDC-Alu-foil blisters of 14 tablets
Carton box containing 4 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 3 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 6 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 2 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 4 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 3 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 7 PVC-PE-PVDC-Alu-foil blisters of 14 tablets each
Carton box containing 7 Alu-Alu -foil blisters blisters of 14 tablets each
Carton box containing 1 Alu-Alu-foil blisters blisters of 14 tablets

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:
Le Vet. B.V.

Marketing authorisation date:
2/03/2010

Manufacturing sites for batch release:
Lelypharma B.V.

Responsible authority:
Norwegian Medical Products Agency

Authorisation number:
07-4741

Date of authorisation status change:
30/01/2013

Reference member state:
Netherlands

Procedure number:
NL/V/0126/003

Concerned member states:
Austria Belgium Czechia Estonia Finland France Ireland Italy Luxembourg Norway Poland Portugal Slovakia Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
